Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

betrixaban

- PMLiVE

J&J’s subcutaneous Rybrevant receives positive CHMP opinion for advanced lung cancer

The formulation significantly reduces administration time compared to the approved intravenous version

- PMLiVE

Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

The rare liver disease affects approximately 15 per 100,000 people in Europe

- PMLiVE

GSK’s Jemperli receives positive CHMP opinion for expanded endometrial cancer use

Approximately 121,000 people are diagnosed with primary advanced or recurrent endometrial cancer each year in Europe

- PMLiVE

Eli Lilly’s Omvoh recommended by CHMP to treat Crohn’s disease in adults

The drug is already approved in the EU to treat ulcerative colitis, another form of inflammatory bowel disease

EU flag

CHMP recommends Galderma’s nemolizumab for atopic dermatitis and prurigo nodularis

The drug has been recommended for use in patients with moderate-to-severe cases of the skin diseases

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug lecanemab receives CHMP recommendation

The neurodegenerative disorder affects an estimated 6.9 million people in Europe

- PMLiVE

BeiGene’s Tevimbra recommended by CHMP for gastric and oesophageal cancer

Gastric cancer is the fifth leading cause of cancer-related deaths globally, while oesophageal cancer is the sixth

- PMLiVE

Novartis’ Kisqali receives CHMP recommendation for early breast cancer patients

Approximately 70% of all breast cancer patients have HR-positive/HER2-negative disease

- PMLiVE

AstraZeneca/Ionis’ Wainzua receives positive CHMP opinion to treat rare disease ATTRv-PN

The drug can be self-administered via an auto-injector and is designed to lower the production of TTR protein at its source

- PMLiVE

Novo Nordisk’s Alhemo recommended by CHMP for haemophilia A and B

The rare bleeding disorder affects approximately 1,125,000 people globally

- PMLiVE

GSK receives CHMP recommendation for meningococcal disease vaccine Menveo

The new presentation would offer healthcare providers an option that does not require reconstitution before use

- PMLiVE

Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation

The updated vaccine was shown to generate an improved response against currently circulating variants

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links